MedTrace Logo

Docetaxel With Rapid Hormonal Cycling as a Treatment for Patients With Prostate Cancer

NCT00587431 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 102

Last updated 2023-11-07

Study results available
· View outcomes & findings →

Summary

We postulate that multiple apoptototic events are indusce through testosterone depletion and repletion with taxotere given in conjunction with androgen withdrawal.

Conditions

Interventions

DRUG

GnRh (Leuprolide)

Leuprolide LUPRON

DRUG

Testosterone Gel

Starting during week 3 (day 19) of cycle 1, 7.5G applied topically daily for 3 days (applied at approximately 9p)

DRUG

Docetaxel

70 mg/m2 given on day o1 of each 3 week cycle

Sponsors & Collaborators

Principal Investigators

  • Dana Rathkopf, MD, PhD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-07-31
Primary Completion
2008-02-29
Completion
2008-02-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00587431 on ClinicalTrials.gov